Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy.

Autor: Liberatore G; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy. Electronic address: giuseppe.liberatore@humanitas.it., Giannotta C; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Sajeev BP; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Morenghi E; Biostatistics Unit, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Terenghi F; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Gallia F; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Doneddu PE; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy., Manganelli F; Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy., Cocito D; Presidio Sanitario Major, Istituti Clinici Scientifici Maugeri, Turin, Italy., Filosto M; Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy., Antonini G; Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy., Cosentino G; Department of Experimental BioMedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy., Marfia GA; Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy., Clerici AM; Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy., Lauria G; Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy; Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy., Rosso T; ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy., Cavaletti G; School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy., Nobile-Orazio E; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Milan, Italy; Department of Medical Biotechnology and Translational Medicine, Milan University, Milan, Italy.
Jazyk: angličtina
Zdroj: Journal of neuroimmunology [J Neuroimmunol] 2020 Aug 15; Vol. 345, pp. 577288. Date of Electronic Publication: 2020 Jun 08.
DOI: 10.1016/j.jneuroim.2020.577288
Abstrakt: For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differentiate CIDP and anti-MAG neuropathy.
Competing Interests: Declaration of Competing Interest E.N.O. reported personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, LFB, France, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. P.E.D. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. G.L. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. D.C. reported honoraria for lecturing from Shire, CSL Behring, and Kedrion and travel grants to attend scientific meeting from Shire, Kedrion, and CSL Behring. G.C. reported travel grants to attend scientific meetings from CSL Behring and Kedrion. F.M. reported personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. G.C. reported honoraria for lecturing and travel grants to attend scientific meetings from Kedrion. M.F. has served on scientific advisory boards for CSL Behring and Sarepta Therapeutics and has received travel grants from Sanofi Genzyme, Kedrion, Baxter and CSL Behring to attend scientific meeting. G.A.M. reported consulence fees and travel fundings from CSL Behring, Kedrion, Shire and Grifols. G.A. reported honoraria for lecturing from Kedrion and Sanofi-genzyme, travel grants from Kedrion, Sanofi-Genzyme and LJ Pharma. The other authors declare no conflict of interest.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: